Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A cDNA library prepared from a human
glioblastoma
cell line has been introduced into a budding yeast strain that lacks CLN1 and CLN2 and is conditionally deficient for
CLN3
function. We rescued a gene that we call cyclin D1. It is related to A-, B-, and CLN-type cyclins, but appears to define a new subclass within the cyclin gene family. Transcription of the cyclin D1 gene gives rise to two major transcripts through alternative polyadenylation. The cyclin D1 gene transcript and its 34 kd product are both abundant in the
glioblastoma
cell line of origin.
...
PMID:Human D-type cyclin. 182 56
Juvenile
Batten disease
is a neurodegenerative disease caused by accelerated apoptotic death of photoreceptors and neurons attributable to defects in the
CLN3
gene.
CLN3
is antiapoptotic when overexpressed in NT2 neuronal precursor cells.
CLN3
negatively modulates endogenous ceramide levels in NT2 cells and acts upstream of ceramide generation. Because defects in regulation of apoptosis are involved in the development of cancer, we evaluated the expression of
CLN3
on both mRNA and protein levels in a variety of cancer cell lines and solid colon cancer tissue. We also observed the effect of the blocking of CLN3 protein expression on cancer cell growth, survival, ceramide production, and apoptosis by using an adenovirus-bearing antisense
CLN3
construct. We show that
CLN3
mRNA and protein are overexpressed in
glioblastoma
(U-373G and T98g), neuroblastoma (IMR-32 and SK-N-MC), prostate (Du145, PC-3, and LNCaP), ovarian (SK-OV-3, SW626, and PA-1), breast (BT-20, BT-549, and BT-474), and colon (SW1116, SW480, and HCT 116) cancer cell lines but not in pancreatic (CAPAN and As-PC-1) or lung (A-549 and NCI-H520) cancer cell lines.
CLN3
is also up-regulated in mouse melanoma and breast carcinoma cancer cell lines. We found
CLN3
expression is 22-330% higher than in corresponding normal colon control tissue in 8 of 10 solid colon tumors. An adenovirus-expressing antisense
CLN3
(Ad-AS-CLN3) blocks CLN3 protein expression in DU-145, BT-20, SW1116, and T98g cancer cell lines as seen by Western blot. Blocking of
CLN3
expression using Ad-AS-
CLN3
inhibits growth and viability of cancer cells. It also causes elevation in endogenous ceramide production through de novo ceramide synthesis and results in increased apoptosis as shown by propidium iodide and JC-1 staining. This suggests that Ad-AS-
CLN3
may be an option for therapy in some cancers. More importantly these results suggest that
CLN3
is a novel molecular target for cancer drug discovery.
...
PMID:The CLN3 gene is a novel molecular target for cancer drug discovery. 1183 May 36